SecBot SecBot
SECBOTREPLAY Home › Report › IMTX

IMTX · Immatics announced that four abstracts from its clinical programs will…

Immatics N.V. · 6-K filed Apr 21, 2026 at 10:40 ET

At the news

BULLISHIMPACT 7/10

6-K filed Apr 21, 2026 at 10:40 ET

Immatics announced that four abstracts from its clinical programs will be presented as oral presentations at the 2026 ASCO Annual Meeting, including Phase 1b data for anzu-cel in melanoma, updated data for IMA203CD8 in gynecologic cancers, and first-in-human results for IMA401. This confirms scientific validation and visibility for its PRAME and MAGEA4/8-targeted therapies.

  • Four oral presentations accepted at ASCO 2026, a top oncology conference
  • Data includes Phase 1b results for anzu-cel in advanced melanoma and uveal melanoma
  • Updated Phase 1a/1b data for IMA203CD8 (GEN2) in gynecologic cancers
  • Updated Phase 1 data for PRAME cell therapy in synovial sarcoma

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access